	US 7,393,869 B2
	Methods of using thiazolidine derivatives to treat cancer or inflammation
Zaihui Zhang, Vancouver (Canada); Timothy S. Daynard, Vancouver (Canada); and Gabriel Bela Kalmar, Richmond (Canada)
Assigned to QLT Inc., Vancouver, BC (Canada)
Appl. No. 10/514,174 PCT Filed May 08, 2003, PCT No. PCT/CA03/00682 § 371(c)(1), (2), (4) Date Jul. 07, 2005, PCT Pub. No. WO03/094916, PCT Pub. Date Nov. 20, 2003.
Claims priority of provisional application 60/379929, filed on May 10, 2002.
Prior Publication US 2006/0183782 A1, Aug. 17, 2006
Int. Cl. A01N 43/82 (2006.01); A61K 31/535 (2006.01)

U.S. Cl. 514—361 [514/236.2]

6 Claims

1. A pharmaceutical composition comprises a pharmaceutically acceptable carrier, diluent or excipient and a compound of formula (Ia):

wherein:

each p is independently 1 to 5;

A is linker of four atoms and is selected from the group consisting of an optionally substituted straight or branched alkylene chain of four carbons, an optionally substituted straight or branched alkenylene chain of four carbons, —R^8a—C(R^2a)—N(R^5a)—, —R^8a—N(R^5a)—C(R^2a)—, —R^8a—O—C(R^2a)—, —R^7a—O—C(R^2a)—R^7a—, —R^8a—O—R^7a—, —R^7a—C(R^2a)—N(R^5a)—S(O)_t— (where t is 0 to 2), —R^8a—N(R^5a)—R^7a, —R^8a—S(O)_t—R^7a— (where t is 0 to 2), —R^9a—N(R^5a)—, —R^9a—O—, and —R^9a—C(R^2a)—;

R^1aand R^2aare each independently ═O or ═S;

R^3ais alkyl, alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, chloro, iodo, bromo, haloalkyl, haloalkoxy, nitro, cyano, —N═N—O—R^11a, —OR^10a, —C(O)OR^10a, —C(O)N(R^10a)₂, —N(R^12a)₂, —N(R^10a)C(O)R^10a, —N(R^10a)C(O)OR^11a, —S(O)_tR^10a(where t is 0 to 2), —S(O)_tN(R^10a)₂(where t is 0 to 2), or heterocyclylalkyl;

R^4ais hydrogen, alkyl, aralkyl, aryl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl or heterocyclylalkyl;

R^5ais hydrogen, alkyl, aralkyl, or aryl;

R^6ais alkenyl, aryl, aralkyl, aralkenyl, cycloalkyl, cycloalkylalkyl, haloalkyl, haloalkoxy, nitro, cyano, —N═N—O—R^11a, —C(O)N(R^10a)₂, —N(R^10a)₂, —N(R^10a)C(O)R^10a, —N(R^10a)C(O)OR^11a, —S(O)_tR^10a(where t is 0 to 2), —S(O)_tN(R^10a)₂(where t is 0 to 2), —S(O)_tNH—R^14a, heterocyclyl or heterocyclylalkyl;

each R^7ais an optionally substituted alkylene chain of one carbon;

each R^8ais an optionally substituted straight or branched alkylene or alkenylene chain of two carbons;

each R^9ais an optionally substituted alkylene chain of three carbons;

each R^10ais hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aralkyl or aryl;

R^11ais hydrogen, alkyl or aralkyl;

R^12ais hydrogen, aryl or aralkyl; and

R^14ais a thiazole;

as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers; or as a solvate or polymorph; or as a pharmaceutically acceptable salt thereof.